Abstract | BACKGROUND: METHODS: RESULTS: PATIENT CHARACTERISTICS: male/female: 44/6, median age 60 years (34-75), median WHO 1 (0-2), adenocarcinoma (n = 42), squamous cell carcinoma (n = 8). Toxicity was mild, and 84 % of the patients completed the whole regimen. Forty-seven patients underwent surgery with a curative intention (transhiatal n = 44, transthoracic n = 3). Pathologic complete tumor regression was achieved in 18 of 47 operated patients (38%). R0 resection was achieved in 45 of 47 operated patients (96%). There were four postoperative deaths (8.5). Postoperative complications were comparable with other studies. After a median follow-up of 41.5 months (21-59) estimated 3- and 5-year survival on an intention-to-treat basis was 56 and 48%. Estimated 3-year survival in responders was 61%, in nonresponders 33%. CONCLUSION: This novel neoadjuvant chemoradiation regimen for treatment of patients with stage II-III esophageal cancer is feasible. Results are encouraging with a high pathologic complete tumor regression and R0 resection rate and an acceptable morbidity and mortality. Preliminary survival data are very promising.
|
Authors | L van de Schoot, E A P M Romme, M J van der Sangen, G J Creemers, G van Lijnschoten, O J Repelaer van Driel, H J T Rutten, G A P Nieuwenhuijzen |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 15
Issue 1
Pg. 88-95
(Jan 2008)
ISSN: 1534-4681 [Electronic] United States |
PMID | 17896144
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carboplatin
- Paclitaxel
- Fluorouracil
|
Topics |
- Adenocarcinoma
(drug therapy, pathology, radiotherapy)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage)
- Carcinoma, Squamous Cell
(drug therapy, pathology, radiotherapy)
- Combined Modality Therapy
- Disease-Free Survival
- Esophageal Neoplasms
(drug therapy, pathology, radiotherapy, therapy)
- Feasibility Studies
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Male
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Paclitaxel
(administration & dosage)
- Prospective Studies
- Remission Induction
- Survival Rate
- Treatment Outcome
|